Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assists Nuevolution in connection with Amgen’s cash offer
Mandate

Vinge assists Nuevolution in connection with Amgen’s cash offer

May 22, 2019 Capital Markets and Public M&A

Vinge has assisted Nuevolution AB (publ) (“Nuevolution”) in connection with the cash offer to the shareholders in Nuevolution by Amgen Inc. (“Amgen”).

Nuevolution is a molecule drug discovery biotech company, listed on Nasdaq Stockholm. 

Amgen is one of the world’s leading biotechnology companies, with a vision deeply rooted in innovative science. Amgen’s shares are listed on Nasdaq in the United States.

Amgen offers SEK 32.50 in cash for every share in Nuevolution. The offer value amounts to approximately SEK 1,610 million.
 
Vinge’s team has primarily consisted of David Andersson, Dain Hård Nevonen, Ludvig Frithiof and William Kåge.

Related

Vinge has represented Inflexion in connection with the acquisition of Mecenat

 Vinge has represented Inflexion in connection with the acquisition of the Mecenat group from IK. The acquisition of Mecenat is the first investment made through Inflexion's new Enterprise Fund VI, and Inflexion's first acquisition in Sweden.
January 14, 2025

Vinge has advised the sellers in connection with the sale of Färskvaruhuset i Göteborg AB

 Färskvaruhuset i Göteborg AB is a Swedish nationwide supplier to the retail sector within meat and poultry as well as charcuterie and delicatessen products. The acquirer was the international food trading company BPI A/S, headquartered in Denmark.
January 13, 2025

Vinge has advised the seller in conjunction with the sale of Lundby Plåt Aktiebolag

 Lundby Plåt Aktiebolag provides services within sheet metal work. The acquirer was the Gothenburg based contracting and construction services company, Göfast Gruppen AB.
January 13, 2025